FLINT, Mich., Nov. 23, 2015 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is a member of the network specialty pharmacies selected to distribute NINLARO® (ixazomib) as a treatment for patients with multiple myeloma who have received at least one prior therapy.
NINLARO® is the first and only oral proteasome inhibitor. Proteasomes are enzymes found in cells that help to break down old or unwanted proteins. NINLARO® disrupts a cancer cells' ability to survive by blocking the proteasome and disrupting protein metabolism.
Multiple myeloma is a hematological (blood) cancer that forms malignant plasma cells in the bone marrow, producing abnormal proteins. Because plasma cells circulate widely in the body, they have the potential to affect many bones, possibly resulting in compression fractures, lytic bone lesions and related pain. According to the National Cancer Institute, about 26,850 Americans will be diagnosed with multiple myeloma in 2015 and 11,240 will die from the disease.
"We are excited to offer patients the first oral proteasome inhibitor as an alternative treatment option for those with multiple myeloma," said Gary Kadlec, president of Diplomat. "This breakthrough therapy will serve as an important treatment option for patients with unmet needs."
NINLARO® is manufactured by Millennium Pharmaceutics, Inc., a wholly-own subsidiary of Takeda Pharmaceutical Company Limited. Please see full prescribing information for NINLARO® at www.NINLARO.com.
To learn more about Diplomat, visit www.diplomat.is.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat's filings with the Securities and Exchange Commission, including "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended December 31, 2014 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients, and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
Kali Lucas, Public Relations Coordinator
810.768.9580 | [email protected]
Gary Rice, RPh, MS, MBA, CSP,
Senior Vice President, Clinical Services,
Education, and Human Resources
810.768.9863 | [email protected]
SOURCE Diplomat Pharmacy, Inc.